Serious inefficiencies are hampering clinical trials of new drugs and treatments, prolonging the suffering of millions. Today’s platform technologies, says Dr. Harsha Rajasimha of Jeeva
Source: ACRP The clinical trial industry must proactively address a record of “historical errors and misbehavior” in its treatment of minority populations if it wants
Clinical trials of new drugs and treatments have a high failure rate. Better planning and technology-aided communication, says Dr. Harsha Rajasimha of Jeeva Trials, can
Evidence linking interventions with health outcomes is vital for healthcare decision-making. Making sound choices about healthcare requires the best possible and quality evidence from clinical
Even though the COVID-19 pandemic raised global awareness of clinical trials, most adults have never seen an advertisement recruiting volunteers to participate. In the U.S.,
Source: Medium In recent years, Big Tech has gotten a bad rep. But of course many tech companies are doing important work making monumental positive
By: Harsha K. Rajasimha, MS, PhD & Sharlene Brown, PhD Clinical trials are the regulatory mechanisms agencies like the Food and Drug Administration (FDA) use
Feb 3, 2021 By Harsha Rajasimha, Ph.D. & Sharlene Brown, Ph.D. Patient groups can optimize patient registries, cross-sectional studies, and/or longitudinal natural history studies to
By Harsha Rajasimha, Ph.D., Founder and CEO The precision medicine paradigm is all about targeting medicines to patient cohorts that are most likely to benefit from
This Startup is on a Mission to Decentralize Cell and Gene Therapy Clinical Trials Author: Steven Surdez, Principal at StoryCore; Article originally published on Biobuzz.io
